Voltage-gated sodium (NaV) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se

Neuroscience Letters

Volumn 566, Issue , 2014, Pages 269-274

  Hill, Andrew J ^a   Jones, Nicholas A ^a,b   Smith, Imogen ^a   Hill, Charlotte L ^a   Williams, Claire M ^a   Stephens, Gary J ^a   Whalley, Benjamin J ^a  

^a UNIVERSITY OF READING   (United Kingdom)

^b Porton Down Science Park   (United Kingdom)

Author keywords

Anticonvulsant; Cannabinoid; Dravet syndrome; Epilepsy; Seizure; Sodium channels

Indexed keywords

ANTICONVULSIVE AGENT; CANNABIGEROL; FLUORESCENT DYE; SODIUM CHANNEL NAV1.1; SODIUM CHANNEL NAV1.2; SODIUM CHANNEL NAV1.5; VERATRIDINE; VOLTAGE GATED SODIUM CHANNEL;

ANIMAL CELL; ARTICLE; BRAIN CELL; BRAIN SLICE; FEMALE; HIPPOCAMPAL CA1 REGION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MEMBRANE POTENTIAL; MEMBRANE RESISTANCE; MOUSE; NONHUMAN; PATCH CLAMP TECHNIQUE; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL;

ANTICONVULSANT; CANNABINOID; DRAVET SYNDROME; EPILEPSY; SEIZURE; SODIUM CHANNELS;

ANIMALS; ANTICONVULSANTS; CANNABIDIOL; CANNABINOIDS; CELLS, CULTURED; CEREBRAL CORTEX; CRICETULUS; FEMALE; HIPPOCAMPUS; HUMANS; MALE; MICE; NEURONS; PATCH-CLAMP TECHNIQUES; PENTYLENETETRAZOLE; RATS, INBRED WKY; SEIZURES; VOLTAGE-GATED SODIUM CHANNEL BLOCKERS;

EID: 84897860455     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.03.013     Document Type: Article

References (29)

1. Lerner M. Marihuana: tetrahydrocannabinol and related compounds. Science 1963, 140(3563):175-176.
2. Hill A.J., Williams C.M., Whalley B.J., Stephens G.J. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol. Ther. 2012, 133(1):79-97.
3. Izzo A.A., Borrelli F., Capasso R., Di Marzo V., Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol. Sci. 2009, 30(10):515-527.
4. Consroe P., Wolkin A. Cannabidiol-antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. J. Pharmacol. Exp. Ther. 1977, 201(1):26-32.
5. Jones N.A., Glyn S.E., Akiyama S., Hill T.D., Hill A.J., Weston S.E., Burnett M.D., Yamasaki Y., Stephens G.J., Whalley B.J., Williams C.M. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure 2012, 21(5):344-352.
6. Jones N.A., Hill A.J., Smith I., Bevan S.A., Williams C.M., Whalley B.J., Stephens G.J. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J. Pharmacol. Exp. Ther. 2010, 332(2):569-577.
7. Cunha J.M., Carlini E.A., Pereira A.E., Ramos O.L., Pimentel C., Gagliardi R., Sanvito W.L., Lander N., Mechoulam R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980, 21(3):175-185.
8. GW Pharmaceuticals, GW Pharmaceuticals commences Phase 1 clinical trial of GWP42006 for the treatment of epilepsy, 2013 02/10/2013; available from: http://www.gwpharm.com/Phase1Epilepsy.aspx.
9. Ross H.R., Napier I., Connor M. Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol. J. Biol. Chem. 2008, 283(23):16124-16134.
10. De Petrocellis L., Ligresti A., Moriello A.S., Allara M., Bisogno T., Petrosino S., Stott C.G., Di Marzo V. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br. J. Pharmacol. 2011, 163(7):1479-1494.
11. De Petrocellis L., Orlando P., Moriello A.S., Aviello G., Stott C., Izzo A.A., Marzo V.Di Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol. (Oxf.) 2012, 204(2):255-266.
12. Qin N., Neeper M.P., Liu Y., Hutchinson T.L., Lubin M.L., Flores C.M. TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J. Neurosci. 2008, 28(24):6231-6238.
13. Schachter S.C. Currently available antiepileptic drugs. Neurotherapeutics 2007, 4(1):4-11.
14. Deiana S., Watanabe A., Yamasaki Y., Amada N., Arthur M., Fleming S., Woodcock H., Dorward P., Pigliacampo B., Close S., Platt B., Riedel G. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Delta(9)-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl) 2012, 219(3):859-873.
15. Biedler J.L., Helson L., Spengler B.A. Morphology and growth: tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res. 1973, 33(11):2643-2652.
16. Cascio M.G., Gauson L.A., Stevenson L.A., Ross R.A., Pertwee R.G. Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Br. J. Pharmacol. 2010, 159(1):129-141.
17. McGrath J.C., Drummond G.B., McLachlan E.M., Kilkenny C., Wainwright C.L. Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br. J. Pharmacol. 2010, 160(7):1573-1576.
18. Hill A.J., Weston S.E., Jones N.A., Smith I., Bevan S.A., Williamson E.M., Stephens G.J., Williams C.M., Whalley B.J. Delta(9)-tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia 2010, 51(8):1522-1532.
19. Consroe P., Benedito M.A., Leite J.R., Carlini E.A., Mechoulam R. Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur. J. Pharmacol. 1982, 83(3-4):293-298.
20. Wallace M.J., Wiley J.L., Martin B.R., DeLorenzo R.J. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur. J. Pharmacol. 2001, 428(1):51-57.
21. Talley E.M., Solorzano G., Lei Q., Kim D., Bayliss D.A. Cns distribution of members of the two-pore-domain (KCNK) potassium channel family. J. Neurosci. 2001, 21(19):7491-7505.
22. Blum R., Kafitz K.W., Konnerth A. Neurotrophin-evoked depolarization requires the sodium channel Na(V)1.9. Nature 2002, 419(6908):687-693.
23. Vetter I., Mozar C.A., Durek T., Wingerd J.S., Alewood P.F., Christie M.J., Lewis R.J. Characterisation of Na(v) types endogenously expressed in human SH-SY5Y neuroblastoma cells. Biochem. Pharmacol. 2012, 83(11):1562-1571.
24. Blumenfeld H., Lampert A., Klein J.P., Mission J., Chen M.C., Rivera M., Dib-Hajj S., Brennan A.R., Hains B.C., Waxman S.G. Role of hippocampal sodium channel Nav1.6 in kindling epileptogenesis. Epilepsia 2009, 50(1):44-55.
25. Catterall W.A., Goldin A.L., Waxman S.G. International Union of Pharmacology XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol. Rev. 2005, 57(4):397-409.
26. Ledgerwood C.J., Greenwood S.M., Brett R.R., Pratt J.A., Bushell T.J. Cannabidiol inhibits synaptic transmission in rat hippocampal cultures and slices via multiple receptor pathways. Br. J. Pharmacol. 2011, 162(1):286-294.
27. Hill A.J., Mercier M.S., Hill T.D., Glyn S.E., Jones N.A., Yamasaki Y., Futamura T., Duncan M., Stott C.G., Stephens G.J., Williams C.M., Whalley B.J. Cannabidivarin is anticonvulsant in mouse and rat. Br. J. Pharmacol. 2012, 167(8):1629-1642.
28. Porter B.E., Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013, 29(3):574-577.
29. Chiron C. Current therapeutic procedures in Dravet syndrome. Dev. Med. Child Neurol. 2011, 53(Suppl. 2):16-18.